Dlouhé nekódující molekuly RNA jako regulátory mitogenem aktivované proteinkinázové dráhy (MAPK) v nádorech


Autoři: Tasharrofi Behnoosh ;  Ghafouri-Fard Soudeh
Působiště autorů: Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Vyšlo v časopise: Klin Onkol 2018; 31(2): 95-102
Kategorie: Přehled
doi: 10.14735/amko201895

Souhrn

Úvod:
Mitogenem aktivovaná proteinkinázová dráha (MAPK) přispívá k regulaci mnoha buněčných funkcí, jako je proliferace a diferenciace buněk, mobilita a apoptóza. Extracelulární signálně regulovaná kináza 1/2 (ERK1/2), c-Jun N-terminální kináza (JNK) /p38 a ERK5 jsou tři hlavní moduly v této dráze. Kaskády Raf-ERK1/2 a JNK přispívají k proliferaci buněk, migraci a přežití a jsou hlavními regulátory maligního fenotypu. Tato dráha je sama regulována několika vnějšími signály, stejně jako bočními signály z jiných signálních drah, které vytvářejí komplexní síť. Dlouhé nekódující RNA (lncRNA) jako hlavní modulátory genové exprese na transkripční a posttranskripční úrovni a také regulují tuto dráhu. Kromě toho můžou lncRNA sloužit jako biomarker a cíl nových léčebných strategií u pacientů s nádory.

Cíl:
Prozkoumat roli lncRNA v regulaci dráhy MAPK.

Závěr:
Vzhledem k úloze této dráhy v patogenezi několika typů nádorů dochází ke změnám exprese lncRNA, které vedou ke změnám v dráze MAPK, což vede k inhibici apoptózy a indukci buněčné proliferace a migrace. Některé lncRNA se navíc podílejí na spojení mezi MAPK a jinými drahami souvisejícími s nádory, jako je dráha PI3K/Akt prostřednictvím regulace určitých sdílených proteinů mezi těmito drahami. Na základě dostupnosti některých protinádorových léčiv, modulujících tuto dráhu, by identifikace lncRNA, ovlivňující tuto dráhu pomohla při vytváření účinných terapií.

Klíčová slova:
RNA – dlouhé nekódování – mitogenem aktivované proteinové kinázy – signální transdukce

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Obdrženo:
5. 12. 2017

Přijato:
5. 2. 2018


Zdroje

1. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: Specific messages from ubiquitous messengers. Mol Cell Biol 1999; 19 (4): 2435–2444.

2. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4 (12): 937–947. doi: 10.1038/nrc1503.

3. Li R, Zhang L, Jia L et al. Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation. Plos One 2014; 9 (6): e100893. doi: 10.1371/journal.pone.0100893.

4. Soudyab M, Iranpour M, Ghafouri-Fard S. The role of long non-coding RNAs in breast cancer. Arch Iran Med 2016; 19 (7): 508–517. doi: 0161907/AIM.0011.

5. Iranpour M, Soudyab M, Geranpayeh L et al. Expression analysis of four long noncoding RNAs in breast cancer. Tumour Biol 2016; 37 (3): 2933–2940. doi: 10.1007/s13277-015-4135-2.

6. Nikpayam E, Tasharrofi B, Sarrafzadeh S et al. The role of long non-coding RNAs in ovarian cancer. Iran Biomed J 2017; 21 (1): 3–15. doi: 10.6091/.21.1.24.

7. Dianatpour A, Ghafouri-Fard S. Long non coding RNA expression intersecting cancer and spermatogenesis: A systematic review. Asian Pac J Cancer Prev 2017; 18 (10): 2601–2610. doi: 10.22034/APJCP.2017.18.10. 2601.

8. Dianatpour A, Ghafouri-Fard S. The role of long non coding RNAs in the repair of dna double strand breaks. Int J Mol Cell Med 2017; 6 (1): 1–12.

9. Melissari MT, Grote P. Roles for long non-coding RNAs in physiology and disease. Pflugers Archiv 2016; 468 (6): 945–958. doi: 10.1007/s00424-016-1804-y.

10. Sarrafzadeh S, Geranpayeh L, Ghafouri-Fard S. Expression analysis of long non-coding PCAT-1in breast cancer. Int J Hematol Oncol Stem Cell Res 2017; 11 (3): 185–191.

11. Nikpayam E, Soudyab M, Tasharrofi B et al. Expression analysis of long non-coding ATB and its putative target in breast cancer. Breast Dis 2017; 37 (1): 11–20. doi: 10.3233/BD-160264.

12. Khorshidi HR, Taheri M, Noroozi R et al. ANRIL genetic variants in iranian breast cancer patients. Cell J 2017; 19 (Suppl 1): 72–78. doi: 10.22074/cellj.2017.4496.

13. Taheri M, Pouresmaeili F, Omrani MD et al. Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population. Biomark Med 2017; 11 (5): 413–422. doi: 10.2217/bmm-2016-0378.

14. Taheri M, Habibi M, Noroozi R et al. HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population. Gene 2017; 613: 20–24. doi: 10.1016/j.gene.2017.02.031.

15. Khorshidi HR, Taheri M, Noroozi R et al. Investigation of the association of HOTAIR single nucleotide polymorphisms and risk of breast cancer in an iranian population. Int J Cancer Manag 2017; 10 (5): e7498. doi: 10.5812/ijcm.7498.

16. Sarrafzadeh S, Geranpayeh L, Tasharrofi B et al. Expression study and clinical correlations of MYC and CCAT2 in breast cancer patients. Iran Biomed J 2017; 21 (5): 303–311.

17. Tasharrofi B, Soudyab M, Nikpayam E et al. Comparative expression analysis of hypoxia-inducible factor-alpha and its natural occurring antisense in breast cancer tissues and adjacent noncancerous tissues. Cell Biochem Funct 2016; 34 (8): 572–578. doi: 10.1002/cbf.3230.

18. Xu XC, Wan XF, Zhang ZR. Long non-coding RNA ANRIL promotes tumorigenesis in glioma via MAPK signaling pathways. Int J Clin Exp Patho 2016; 9 (10): 10803–10809.

19. Gooding AJ, Zhang B, Jahanbani FK et al. The lncRNA BORG drives breast cancer metastasis and disease recurrence. Sci Rep 2017; 7: 12698. doi: 10.1038/s41598-017-12716-6.

20. Wang DN, Wang DB, Wang N et al. Long non-coding RNA BANCR promotes endometrial cancer cell proliferation and invasion by regulating MMP2 and MMP1 via ERK/MAPK signaling pathway. Cell Physiol Biochem 2016; 40 (3–4): 644–656. doi: 10.1159/000452577.

21. Quo QH, Zhao Y, Chen JJ et al. BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. Oncol Lett 2014; 8 (2): 869–875. doi: 10.3892/ol.2014.2154.

22. Jiang WJ, Zhang DD, Xu BN et al. Long non-coding RNA BANCR promotes proliferation and migration of lung carcinoma via MAPK pathways. Biomed Pharmacother 2015; 69: 90–95. doi: 10.1016/j.biopha.2014.11.027.

23. Baldinu P, Cossu A, Manca A et al. Identification of a novel candidate gene, CASC2, in a region of common allelic loss at chromosome 10q26 in human endometrial cancer. Hum Mutat 2004; 23 (4): 318–326. doi: 10.1002/humu.20015.

24. Baldinu P, Cossu A, Manca A et al. CASC2a gene is down-regulated in endometrial cancer. Anticancer Res 2007; 27 (1A): 235–243.

25. Wang P, Liu YH, Yao YL et al. Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21. Cell Signal 2015; 27 (2): 275–282. doi: 10.1016/j.cellsig.2014.11.011.

26. Cao Y, Xu R, Xu X et al. Downregulation of lncRNA CASC2 by microRNA-21 increases the proliferation and migration of renal cell carcinoma cells. Mol Med Rep 2016; 14 (1): 1019–1025. doi: 10.3892/mmr.2016.5337.

27. He X, Liu Z, Su J et al. Low expression of long noncoding RNA CASC2 indicates a poor prognosis and regulates cell proliferation in non-small cell lung cancer. Tumour Biol 2016; 37 (7): 9503–9510. doi: 10.1007/s13277-016-4787-6.

28. Huang G, Wu X, Li S et al. The long noncoding RNA CASC2 functions as a competing endogenous RNA by sponging miR-18a in colorectal cancer. Sci Rep 2016 20; 6: 26524. doi: 10.1038/srep26524.

29. Gan Y, Han N, He X et al. Long non-coding RNA CASC2 regulates cell biological behaviour through the MAPK signalling pathway in hepatocellular carcinoma. Tumor Biol 2017; 39 (6): 1010428317706229. doi: 10.1177/1010428317706229.

30. Li P, Xue WJ, Feng Y et al. Long non-coding RNA CASC2 suppresses the proliferation of gastric cancer cells by regulating the MAPK signaling pathway. Am J Transl Res 2016; 8 (8): 3522–3529.

31. Gao R, Zhang R, Zhang C et al. Long noncoding RNA CCAT1 promotes cell proliferation and metastasis in human medulloblastoma via MAPK pathway. Tumori 2017: 0. doi: 10.5301/tj.5000662.

32. Graham LD, Pedersen SK, Brown GS et al. Colorectal neoplasia differentially expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas. Genes Cancer 2011; 2 (8): 829–840. doi: 10.1177/1947601911431081.

33. Ellis BC, Molloy PL, Graham LD. CRNDE: a long non-coding RNA involved in cancer, neurobiology, and development. Front Genet 2012; 3: 270. doi: 10.3389/fgene.2012.00270.

34. Zheng J, Li X, Wang P et al. CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186. Oncotarget 2015; 6 (28): 25339–25355. doi: 10.18632/oncotarget.4509.

35. Szafron LM, Balcerak A, Grzybowska EA et al. The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients. Oncotarget 2015; 6 (41): 43897–43910. doi: 10.18632/oncotarget.6016.

36. Liu T, Zhang X, Yang Y et al. Increased expression of the long noncoding RNA CRNDE-h indicates a poor prognosis in colorectal cancer, and is positively correlated with IRX5 mRNA expression. Onco Targets Ther 2016; 9: 1437–1448. doi: 10.2147/OTT.S98268.

37. Jiang H, Wang Y, Ai M et al. Long noncoding RNA CRNDE stabilized by hnRNPUL2 accelerates cell proliferation and migration in colorectal carcinoma via activating Ras/MAPK signaling pathways. Cell Death Dis 2017; 8 (6): e2862. doi: 10.1038/cddis.2017.258.

38. Van Grembergen O, Bizet M, de Bony EJ et al. Portraying breast cancers with long noncoding RNAs. Sci Adv 2016; 2 (9): e 1600220. doi: 10.1126/sciadv.1600220.

39. Bao H, Guo CG, Qiu PC et al. Long non-coding RNA Igf2as controls hepatocellular carcinoma progression through the ERK/MAPK signaling pathway. Oncol Lett 2017; 14 (3): 2831–2837. doi: 10.3892/ol.2017. 6492.

40. Loewer S, Cabili MN, Guttman M et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet 2010; 42 (12): 1113–1117. doi: 10.1038/ng.710.

41. Wang Y, Xu Z, Jiang J et al. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell 2013; 25 (1): 69–80. doi: 10.1016/j.devcel.2013.03.002.

42. Zhang A, Zhou N, Huang J et al. The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res 2013; 23 (3): 340–350. doi: 10.1038/cr.2012.164.

43. Huang J, Zhang A, Ho TT et al. Linc-RoR promotes c-Myc expression through hnRNP I and AUF1. Nucleic Acids Res 2016; 44 (7): 3059–3069. doi: 10.1093/nar/gkv1353.

44. Eades G, Wolfson B, Zhang Y et al. LincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res 2015; 13 (2): 330–338. doi: 10.1158/1541-7786.MCR-14-0251.

45. Peng WX, Huang JG, Yang L et al. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer. Mol Cancer 2017; 16 (1): 161. doi: 10.1186/s12943-017-0727-3.

46. Zhao XD, Liu YB, Yu S. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker. Biochim Biophys Acta 2017; 1863 (7): 1805–1816. doi: 10.1016/j.bbadis.2017.04.014.

47. Wang AQ, Meng MZ, Zhao XH et al. Long non-coding RNA ENST00462717 suppresses the proliferation, survival, and migration by inhibiting MDM2/MAPK pathway in glioma. Biochem Biophys Res Commun 2017; 485 (2): 513–521. doi: 10.1016/j.bbrc.2017.02.015.

48. Chen L, Sun L, Dong L et al. The role of long noncoding RNA-LET in cell proliferation and invasion of nasopharyngeal carcinoma and its mechanism. Onco Targets Ther 2017; 10: 2769–2778. doi: 10.2147/OTT.S126907.

49. Ying L, Chen Q, Wang Y et al. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst 2012; 8 (9): 2289–2294. doi: 10.1039/c2mb25070e.

50. Wu XS, Wang XA, Wu WG et al. MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol Ther 2014; 15 (6): 806–814. doi: 10.4161/cbt.28584.

51. Gutschner T, Hämmerle M, Eißmann M et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 2013; 73 (3): 1180–1189. doi: 10.1158/0008-5472.CAN-12-2850.

52. Yiu GK, Kaunisto A, Chin YR et al. NFAT promotes carcinoma invasive migration through glypican-6. Biochemical J 2011; 440 (1): 157–166. doi: 10.1042/BJ20110 530.

53. Merabova N, Kaminski R, Krynska B et al. JCV agnoprotein-induced reduction in CXCL5/LIX secretion by oligodendrocytes is associated with activation of apoptotic signaling in neurons. J Cell Physiol 2012; 227 (8): 3119–3127. doi: 10.1002/jcp.23065.

54. Chen L, Feng PM, Zhu X et al. Long non-coding RNA Malat1 promotes neurite outgrowth through activation of ERK/MAPK signalling pathway in N2a cells. J Cell Mol Med 2016; 20 (11): 2102–2110. doi: 10.1111/jcmm.12904.

55. Li JK, Chen C, Liu JY et al. Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling. Mol Cancer 2017; 16 (1): 111. doi: 10.1186/s12943-017-0681-0.

56. Zhang X, Zhou YL, Mehta KR et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 2003; 88 (11): 5119–5126. doi: 10.1210/jc.2003-030222.

57. Wang PJ, Ren ZQ, Sun PY. Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J Cell Biochem 2012; 113 (6): 1868–1874. doi: 10.1002/jcb.24055.

58. Zhang X, Gejman R, Mahta A et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res 2010; 70 (6): 2350–2358. doi: 10.1158/0008-5472.CAN-09-3885.

59. Zhu J, Liu S, Ye F et al. Long Noncoding RNA MEG3 Interacts with p53 protein and regulates partial p53 target genes in hepatoma cells. Plos One 2015; 10 (10): e0139790. doi: 10.1371/journal.pone.0139790.

60. Sun M, Xia R, Jin F et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour biology 2014; 35 (2): 1065–1073. doi: 10.1007/s13277-013-1142-z.

61. Zhang CY, Yu MS, Li X et al. Overexpression of long non-coding RNA MEG3 suppresses breast cancer cell proliferation, invasion, and angiogenesis through AKT pathway. Tumour Biol 2017; 39 (6): 1010428317701311. doi: 10.1177/1010428317701311.

62. Chen XJ, Dong H, Liu S et al. Long noncoding RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated PI3K-Akt pathway. Am J Transl Res 2017; 9 (1): 90–102.

63. Patel Y, Shah N, Lee JS et al. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth. Oncotarget 2016; 7 (14): 18295–18308. doi: 10.18632/oncotarget.7577.

64. Chen S, Wang Y, Zhang JH et al. Long non-coding RNA PTENP1 inhibits proliferation and migration of breast cancer cells via AKT and MAPK signaling pathways. Oncol Lett 2017; 14 (4): 4659–4662. doi: 10.3892/ol.2017.6823.

65. Goedert L, Pereira CG, Roszik J et al. RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma. Oncotarget 2016; 7 (24): 36711–36718. doi: 10.18632/oncotarget. 9164.

66. Zhang EB, Yin DD, Sun M et al. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. Cell Death Dis 2014; 5: e1243. doi: 10.1038/cddis.2014.201.

67. Yang C, Li X, Wang Y et al. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene 2012; 496 (1): 8–16. doi: 10.1016/j.gene.2012.01.012.

68. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases (vol 75, pg 50, 2011). Microbiol Mol Biol Rev 2012; 76 (2): 496. doi: 10.1128/MMBR.00013-12.

69. Xu WH, Zhang JB, Dang Z et al. Long Non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma. Int J Biol Sci 2014; 10 (7): 664–676. doi: 10.7150/ijbs.8232.

70. Taheri M, Omrani MD, Ghafouri-Fard S. Long non-coding RNAs expression in renal cell carcinoma. Journal of Biology and Today‘s World 2017; 6 (12): 240–247.

71. Faramarzi S, Dianatpour A, Ghafouri-Fard S. Discovering the role of long non-coding RNAs in regulation of steroid receptors signaling in cancer. Journal of Biology and Today‘s World 2017; 6 (12): 248–258.

72. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. Biochem Pharmacol 2010; 80 (5): 624–637. doi: 10.1016/j.bcp.2010.04. 029.

73. Riddick G, Kotliarova S, Rodriguez V et al. A core regulatory circuit in glioblastoma stem cells links MAPK activation to a transcriptional program of neural stem cell identity. Sci Rep 2017; 7: 43605. doi: 10.1038/srep43 605.

74. Dong YQ, Liang GJ, Yuan B et al. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol 2015; 36 (3): 1477–1486. doi: 10.1007/s13277-014-2631-4.

75. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochemical Soc Trans 2012; 40 (1): 139–146. doi: 10.1042/BST20110609.

76. Taylor AD, Micheel CM, Anderson IA et al. The path (way) less traveled: a pathway-oriented approach to providing information about precision cancer medicine on my cancer genome. Transl Oncol 2016; 9 (2): 163–165. doi: 10.1016/j.tranon.2016.03.001.

Štítky
Dětská onkologie Chirurgie všeobecná Onkologie

Článek vyšel v časopise

Klinická onkologie

Číslo 2

2018 Číslo 2

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se